Hawaii 2023 Regular Session

Hawaii House Bill HB966 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	HOUSE OF REPRESENTATIVES H.B. NO. 966 THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII A BILL FOR AN ACT relating to access to treatment for terminally ill patients. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	HOUSE OF REPRESENTATIVES H.B. NO. 966
4	4	THIRTY-SECOND LEGISLATURE, 2023
5	5	STATE OF HAWAII
6	6
7	7	HOUSE OF REPRESENTATIVES
8	8
9	9	H.B. NO.
10	10
11	11	966
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	relating to access to treatment for terminally ill patients.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. The legislature finds that the process of approval for investigational drugs and biological products in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over the long run, but the process often takes many years. Patients who have a terminal illness can be severely restricted in care options until an investigational drug or biological product receives final approval from the United States Food and Drug Administration. The legislature further finds that because patients who have a terminal illness may often not have the time to wait for a potentially lifesaving investigational drug or biological product to gain final approval from the United States Food and Drug Administration, the federal government and forty-one states have enacted "right-to-try" legislation that makes available experimental drugs without Food and Drug Administration approval to terminally ill patients with no other medication or treatment options. The purpose of this Act is to grant patients with terminal illnesses access to potentially life-saving investigational drugs and biological products that have not received final approval from the United States Food and Drug Administration. SECTION 2. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows: "§321- Access to investigational drugs and biological products for terminally ill patients. (a) Notwithstanding section 328-17, beginning January 1, 2024, a manufacturer of an investigational drug or biological product may make available the manufacturer's investigational drug or biological product to eligible patients pursuant to this section. This section does not require that a manufacturer make available an investigational drug or biological product to an eligible patient. A manufacturer may: (1) Provide an investigational drug or biological product to an eligible patient without receiving compensation; or (2) Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug or biological product. (b) A health insurance carrier may, but is not required to, provide coverage for the cost of an investigational drug or biological product. (c) An insurer may deny coverage to an eligible patient from the time the eligible patient begins use of the investigational drug or biological product through a period not to exceed six months from the time the investigational drug or biological product is no longer used by the eligible patient; provided that coverage may not be denied for a preexisting condition and for coverage for benefits that commence prior to the time the eligible patient begins use of the investigational drug or biological product. (d) If a patient dies while being treated by an investigational drug or biological product, the patient's heirs shall not be liable for any outstanding debt related to the treatment or lack of insurance due to the treatment. (e) Notwithstanding any law to the contrary, a licensing board may not revoke, fail to renew, suspend, or take any action against a health care provider's license based on the health care provider's recommendations to an eligible patient regarding access to or treatment with an investigational drug or biological product that is being developed to treat the type of terminal illness that afflicts the patient, any physical or psychological symptoms of the patient's terminal illness, or for palliative care. Action against a health care provider's medicare certification based on the health care provider's recommendation that a patient have access to an investigational drug or biological product that is being developed to treat the type of terminal illness that afflicts the patient, any physical or psychological symptoms of the patient's terminal illness, or for palliative care shall be prohibited. (f) An official, employee, or agent of the State shall not block or attempt to block an eligible patient's access to an investigational drug or biological product. Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider shall not constitute a violation of this section. (g) This section does not create a private cause of action against a manufacturer of an investigational drug or biological product or against another person or entity involved in the care of an eligible patient using the investigational drug or biological product, for any harm done to the eligible patient resulting from the investigational drug or biological product; provided that the manufacturer or other person or entity is complying in good faith with the terms of this section; provided further there was no failure to exercise reasonable care. (h) For the purposes of this section: "Eligible patient" means a person who has: (1) A terminal illness, attested to by the patient's treating physician; (2) Considered all other treatment options currently approved by the United States Food and Drug Administration; (3) Been unable to participate in a clinical trial for the terminal illness within one hundred miles of the patient's home address for the terminal illness, or not been accepted to the clinical trial within one week of completion of the clinical trial application process; (4) Received a recommendation from the patient's physician for an investigational drug or biological product in order to treat the patient's terminal illness, physical or psychological symptoms of the patient's terminal illness, or for palliative care; (5) Given written, informed consent for the use of the investigational drug or biological product or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written, informed consent on the patient's behalf; and (6) Documentation from the patient's physician that the patient meets the requirements of this definition. "Eligible patient" does not include a person being treated as an inpatient in an institution with an organized medical staff, regulated under section 321-11(10), or a health care facility under chapter 323F. "Investigational drug or biological product" means a drug or biological product that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a United States Food and Drug Administration-approved clinical trial. "Terminal illness" means a disease that, without life-sustaining procedures, will result in death or a state of permanent unconsciousness from which recovery is unlikely. "Written, informed consent" means a written document signed by the patient and attested to by the patient's physician and a witness that, at a minimum: (1) Explains the currently approved products and treatments for the disease or condition from which the patient suffers; (2) Attests to the fact that the patient concurs with the patient's physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient's life; (3) Clearly identifies the specific proposed investigational drug or biological product that the patient is seeking to use; (4) Describes the potentially best and worst outcomes of using the investigational drug or biological product with a realistic description of the most likely outcome, including the possibility that new, unanticipated, different, or worse symptoms might result, and that death could be hastened by the proposed treatment, based on the physician's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition; (5) Makes clear that the patient's health insurer and provider are not obligated to pay for any care or treatments consequent to the use of the investigational drug or biological product; (6) Makes clear that the patient's eligibility for hospice care may be withdrawn by the hospice care provider if the patient begins curative treatment and care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements; (7) Makes clear that in-home health care may be denied if treatment begins; and (8) States that the patient understands that the patient is liable for all expenses consequent to the use of the investigational drug or biological product, and that this liability extends to the patient's estate, unless a contract between the patient and the manufacturer of the investigational drug or biological product states otherwise." SECTION 3. New statutory material is underscored. SECTION 4. This Act shall take effect upon its approval. INTRODUCED BY: _____________________________
48	48
49	49	SECTION 1. The legislature finds that the process of approval for investigational drugs and biological products in the United States protects future patients from premature, ineffective, and unsafe medications and treatments over the long run, but the process often takes many years. Patients who have a terminal illness can be severely restricted in care options until an investigational drug or biological product receives final approval from the United States Food and Drug Administration.
50	50
51	51	The legislature further finds that because patients who have a terminal illness may often not have the time to wait for a potentially lifesaving investigational drug or biological product to gain final approval from the United States Food and Drug Administration, the federal government and forty-one states have enacted "right-to-try" legislation that makes available experimental drugs without Food and Drug Administration approval to terminally ill patients with no other medication or treatment options.
52	52
53	53	The purpose of this Act is to grant patients with terminal illnesses access to potentially life-saving investigational drugs and biological products that have not received final approval from the United States Food and Drug Administration.
54	54
55	55	SECTION 2. Chapter 321, Hawaii Revised Statutes, is amended by adding a new section to be appropriately designated and to read as follows:
56	56
57	57	"§321- Access to investigational drugs and biological products for terminally ill patients. (a) Notwithstanding section 328-17, beginning January 1, 2024, a manufacturer of an investigational drug or biological product may make available the manufacturer's investigational drug or biological product to eligible patients pursuant to this section. This section does not require that a manufacturer make available an investigational drug or biological product to an eligible patient. A manufacturer may:
58	58
59	59	(1) Provide an investigational drug or biological product to an eligible patient without receiving compensation; or
60	60
61	61	(2) Require an eligible patient to pay the costs of, or the costs associated with, the manufacture of the investigational drug or biological product.
62	62
63	63	(b) A health insurance carrier may, but is not required to, provide coverage for the cost of an investigational drug or biological product.
64	64
65	65	(c) An insurer may deny coverage to an eligible patient from the time the eligible patient begins use of the investigational drug or biological product through a period not to exceed six months from the time the investigational drug or biological product is no longer used by the eligible patient; provided that coverage may not be denied for a preexisting condition and for coverage for benefits that commence prior to the time the eligible patient begins use of the investigational drug or biological product.
66	66
67	67	(d) If a patient dies while being treated by an investigational drug or biological product, the patient's heirs shall not be liable for any outstanding debt related to the treatment or lack of insurance due to the treatment.
68	68
69	69	(e) Notwithstanding any law to the contrary, a licensing board may not revoke, fail to renew, suspend, or take any action against a health care provider's license based on the health care provider's recommendations to an eligible patient regarding access to or treatment with an investigational drug or biological product that is being developed to treat the type of terminal illness that afflicts the patient, any physical or psychological symptoms of the patient's terminal illness, or for palliative care. Action against a health care provider's medicare certification based on the health care provider's recommendation that a patient have access to an investigational drug or biological product that is being developed to treat the type of terminal illness that afflicts the patient, any physical or psychological symptoms of the patient's terminal illness, or for palliative care shall be prohibited.
70	70
71	71	(f) An official, employee, or agent of the State shall not block or attempt to block an eligible patient's access to an investigational drug or biological product. Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider shall not constitute a violation of this section.
72	72
73	73	(g) This section does not create a private cause of action against a manufacturer of an investigational drug or biological product or against another person or entity involved in the care of an eligible patient using the investigational drug or biological product, for any harm done to the eligible patient resulting from the investigational drug or biological product; provided that the manufacturer or other person or entity is complying in good faith with the terms of this section; provided further there was no failure to exercise reasonable care.
74	74
75	75	(h) For the purposes of this section:
76	76
77	77	"Eligible patient" means a person who has:
78	78
79	79	(1) A terminal illness, attested to by the patient's treating physician;
80	80
81	81	(2) Considered all other treatment options currently approved by the United States Food and Drug Administration;
82	82
83	83	(3) Been unable to participate in a clinical trial for the terminal illness within one hundred miles of the patient's home address for the terminal illness, or not been accepted to the clinical trial within one week of completion of the clinical trial application process;
84	84
85	85	(4) Received a recommendation from the patient's physician for an investigational drug or biological product in order to treat the patient's terminal illness, physical or psychological symptoms of the patient's terminal illness, or for palliative care;
86	86
87	87	(5) Given written, informed consent for the use of the investigational drug or biological product or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian has given written, informed consent on the patient's behalf; and
88	88
89	89	(6) Documentation from the patient's physician that the patient meets the requirements of this definition.
90	90
91	91	"Eligible patient" does not include a person being treated as an inpatient in an institution with an organized medical staff, regulated under section 321-11(10), or a health care facility under chapter 323F.
92	92
93	93	"Investigational drug or biological product" means a drug or biological product that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a United States Food and Drug Administration-approved clinical trial.
94	94
95	95	"Terminal illness" means a disease that, without life-sustaining procedures, will result in death or a state of permanent unconsciousness from which recovery is unlikely.
96	96
97	97	"Written, informed consent" means a written document signed by the patient and attested to by the patient's physician and a witness that, at a minimum:
98	98
99	99	(1) Explains the currently approved products and treatments for the disease or condition from which the patient suffers;
100	100
101	101	(2) Attests to the fact that the patient concurs with the patient's physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient's life;
102	102
103	103	(3) Clearly identifies the specific proposed investigational drug or biological product that the patient is seeking to use;
104	104
105	105	(4) Describes the potentially best and worst outcomes of using the investigational drug or biological product with a realistic description of the most likely outcome, including the possibility that new, unanticipated, different, or worse symptoms might result, and that death could be hastened by the proposed treatment, based on the physician's knowledge of the proposed treatment in conjunction with an awareness of the patient's condition;
106	106
107	107	(5) Makes clear that the patient's health insurer and provider are not obligated to pay for any care or treatments consequent to the use of the investigational drug or biological product;
108	108
109	109	(6) Makes clear that the patient's eligibility for hospice care may be withdrawn by the hospice care provider if the patient begins curative treatment and care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements;
110	110
111	111	(7) Makes clear that in-home health care may be denied if treatment begins; and
112	112
113	113	(8) States that the patient understands that the patient is liable for all expenses consequent to the use of the investigational drug or biological product, and that this liability extends to the patient's estate, unless a contract between the patient and the manufacturer of the investigational drug or biological product states otherwise."
114	114
115	115	SECTION 3. New statutory material is underscored.
116	116
117	117	SECTION 4. This Act shall take effect upon its approval.
118	118
119	119
120	120
121	121	INTRODUCED BY: _____________________________
122	122
123	123	INTRODUCED BY:
124	124
125	125	_____________________________
126	126
127	127
128	128
129	129
130	130
131	131	Report Title: Right-to-Try Act; Terminally Ill Patients; Investigational Drugs; Biological Products Description: Beginning on January 1, 2024, permits manufacturers of investigational drugs or biological products to make these drugs and products available to terminally ill patients under certain conditions. The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
132	132
133	133
134	134
135	135
136	136
137	137	Report Title:
138	138
139	139	Right-to-Try Act; Terminally Ill Patients; Investigational Drugs; Biological Products
140	140
141	141
142	142
143	143	Description:
144	144
145	145	Beginning on January 1, 2024, permits manufacturers of investigational drugs or biological products to make these drugs and products available to terminally ill patients under certain conditions.
146	146
147	147
148	148
149	149
150	150
151	151
152	152
153	153	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.